Evidence for the therapeutic utility of helper T cells is shown in murine models of glioblastoma multiforme where CD4+ CAR-T cells were found to perform better than CD8+ CAR-T cells, particularly in terms of exhibiting long-term anti-tumor immunity (39). This evidence concerns the gene CD4 and glioblastoma.